Wall Street brokerages predict that Agenus Inc (NASDAQ:AGEN) will report earnings of ($0.25) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Agenus’ earnings, with estimates ranging from ($0.26) to ($0.24). Agenus posted earnings per share of ($0.37) in the same quarter last year, which would indicate a positive year-over-year growth rate of 32.4%. The company is expected to report its next quarterly earnings results on Tuesday, November 6th.
According to Zacks, analysts expect that Agenus will report full year earnings of ($1.31) per share for the current fiscal year, with EPS estimates ranging from ($1.33) to ($1.28). For the next financial year, analysts forecast that the firm will report earnings of ($1.46) per share, with EPS estimates ranging from ($1.47) to ($1.44). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Agenus.
Agenus (NASDAQ:AGEN) last posted its earnings results on Thursday, August 9th. The biotechnology company reported ($0.24) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.16.
A number of research firms recently commented on AGEN. BidaskClub cut shares of Agenus from a “strong-buy” rating to a “buy” rating in a report on Monday, June 18th. Zacks Investment Research cut shares of Agenus from a “hold” rating to a “sell” rating in a report on Monday, July 23rd.
NASDAQ:AGEN opened at $2.14 on Monday. The company has a debt-to-equity ratio of -0.11, a current ratio of 1.32 and a quick ratio of 1.32. Agenus has a 12 month low of $1.55 and a 12 month high of $6.19.
Large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. bought a new stake in shares of Agenus in the 1st quarter worth approximately $197,000. UBS Group AG raised its holdings in shares of Agenus by 1,180.3% in the 1st quarter. UBS Group AG now owns 137,417 shares of the biotechnology company’s stock worth $647,000 after purchasing an additional 126,684 shares during the period. BlackRock Inc. raised its holdings in shares of Agenus by 1.2% in the 1st quarter. BlackRock Inc. now owns 4,941,251 shares of the biotechnology company’s stock worth $23,272,000 after purchasing an additional 58,030 shares during the period. Allianz Asset Management GmbH raised its holdings in shares of Agenus by 6.3% in the 1st quarter. Allianz Asset Management GmbH now owns 245,965 shares of the biotechnology company’s stock worth $1,158,000 after purchasing an additional 14,634 shares during the period. Finally, Northern Trust Corp raised its holdings in shares of Agenus by 4.0% in the 1st quarter. Northern Trust Corp now owns 964,199 shares of the biotechnology company’s stock worth $4,541,000 after purchasing an additional 37,027 shares during the period. 35.34% of the stock is currently owned by institutional investors.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Featured Article: Technical Analysis
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.